Acipimox sodium  (Synonyms: K-9321 sodium)

Acipimox (K-9321) sodium, a nicotinic acid analogue, is an antilipolytic compound. Acipimox sodium stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity^[1][2][3].

Acipimox sodium (0-100 µM; 0-4 hours) enhances leptin release from adipocytes isolated from Sprague-Dawley rats in a time- and dose- dependent manner^[2].
Acipimox sodium (10 mM) stimulats leptin release in adipocytes from Streptozotocin (STZ)-treated and Zucker diabetic fat (ZDF) rats^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Acipimox sodium (50 mg/kg; i.p.) significantly lowers circulating free fatty acid (FFA) and glucose in high-fat fed mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

176.11

C₆H₅N₂NaO₃

76958-97-9

O=C(C1=C[N+]([O-])=C(C)C=N1)O[Na]

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Vestergaard ET, et, al. Short-term acipimox treatment is associated with decreased cardiac parasympathetic modulation. Br J Clin Pharmacol. 2017 Dec;83(12):2671-2677.  [Content Brief]

  [2]. Wang-Fisher YL, et, al. Acipimox stimulates leptin production from isolated rat adipocytes. J Endocrinol. 2002 Aug;174(2):267-72.  [Content Brief]

  [3]. Ahrén B. Reducing plasma free fatty acids by acipimox improves glucose tolerance in high-fat fed mice. Acta Physiol Scand. 2001 Feb;171(2):161-7.  [Content Brief]